Kim Forest Enterprise Co., Ltd. (TPE:6645)
Taiwan · Delayed Price · Currency is TWD 13.00
-0.10 (-0.76%)
Apr 24, 2026, 1:30 PM CST
Kim Forest Enterprise Revenue
In the year 2025, Kim Forest Enterprise had annual revenue of 549.14M TWD with 9.49% growth. Kim Forest Enterprise had revenue of 176.90M in the quarter ending December 31, 2025, with 11.02% growth.
Revenue
549.14M
Revenue Growth
+9.49%
P/S Ratio
1.44
Revenue / Employee
n/a
Employees
n/a
Market Cap
788.11M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 549.14M | 47.62M | 9.49% |
| Dec 31, 2024 | 501.53M | 86.52M | 20.85% |
| Dec 31, 2023 | 415.01M | -255.58M | -38.11% |
| Dec 31, 2022 | 670.59M | 69.92M | 11.64% |
| Dec 31, 2021 | 600.67M | 297.78M | 98.31% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Lotus Pharmaceutical | 20.51B |
| PharmaEssentia | 15.63B |
| Yung Zip Chemical Ind. | 474.22M |
| Radiant Innovation | 387.58M |
| Sofiva Genomics | 385.71M |
| BioLASCO Taiwan | 262.66M |
| Puriblood Medical | 117.35M |
| Caliway Biopharmaceuticals | 38.04M |